Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-05-13 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION - CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED AUGTYRO (REPOTRECTINIB) FOR TREATMENT OF PATIENTS WITH ROS1-POSITIVE NSCLC
Regulatory Filings Classification · 95% confidence The document is an announcement by Zai Lab Limited regarding the approval of a new drug by China's National Medical Products Administration. It is labeled as "INSIDE INFORMATION" and references compliance with listing rules and inside information provisions. The content is a brief announcement about regulatory approval of a drug, not a financial report, earnings release, or management discussion. The document length is short (2310 characters) and it does not contain financial data or detailed report content. It is an announcement of significant company news related to regulatory approval, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like earnings, annual report, or management information.
2024-05-13 English
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q
Interim / Quarterly Report Classification · 100% confidence The document is titled 'OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q' and references the filing of a Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, with the U.S. SEC. The text includes detailed financial statements, management discussion and analysis, risk factors, and other typical contents of a quarterly report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of unaudited condensed consolidated financial statements and management's discussion confirms it is a comprehensive quarterly report. Therefore, the document is classified as an Interim / Quarterly Report (IR).
2024-05-09 English
UNAUDITED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND CORPORATE UPDATES
Interim / Quarterly Report Classification · 95% confidence The document is titled 'UNAUDITED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND CORPORATE UPDATES' and contains detailed financial data for the first quarter of 2024, including product revenues, expenses, net loss, and cash position. It also includes corporate updates, pipeline highlights, and anticipated milestones. The document references the SEC and U.S. GAAP, indicating it is a formal financial disclosure. The length is about 15,000 characters, which is substantial and contains actual financial statements and analysis, not just an announcement or summary. The content matches the characteristics of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year with substantive financial data and management commentary. It is not a mere earnings release (ER) because it provides detailed financials and corporate updates beyond key highlights. It is not a call transcript (CT) despite mentioning a conference call, as the text itself is not a transcript. Therefore, the correct classification is Interim / Quarterly Report (IR).
2024-05-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued share capital, share options, and other share-related movements for Zai Lab Limited. It includes data on share capital balances, share options under various equity incentive plans, and confirmations related to securities issuance. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. It is not an announcement of a report but contains substantive data on share capital and securities movements for the month ended April 30, 2024. This type of document aligns with disclosures related to share capital changes and share issuance activities rather than financial results, management commentary, or governance. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2024-05-07 English
2024 EQUITY INCENTIVE PLAN
Regulatory Filings Classification · 95% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2024-04-30 English
PROXY CARD
Regulatory Filings
2024-04-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.